Physician profile
Peter G Ting
NPI 1023512449
$17,209.63
in general payments reported to CMS, 2019-2025
12 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.99 · 2023: $110 · 2024: $638 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $13K · Food and Beverage: $2,027 · Travel and Lodging: $1,810 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $13,124.00 |
| Food and Beverage | $2,026.75 |
| Travel and Lodging | $1,809.64 |
| Education | $159.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,477.58 | 2025 | Emblem Mri S-Icd, General - Therapies, Farapulse |
| Abbott Laboratories | $6,008.05 | 2023-2025 | Assurity, Tacticath, Aveir |
| Medtronic, INC. | $3,541.63 | 2023-2025 | Abre |
| Biotronik INC. | $897.54 | 2024-2025 | Acticor 7 Vr-T Dx, Zero Gravity |
| Astellas Pharma US INC | $89.99 | 2022 | |
| Nuwellis, INC. | $37.13 | 2023 | Aquadex Smartflow Console |
| Amgen INC. | $30.63 | 2025 | Repatha |
| Cardiva Medical, INC. | $29.51 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Angiodynamics, INC. | $26.05 | 2025 | Angiovac |
| Pfizer INC. | $24.55 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.62 | 2024 | Jardiance |
| Kestra Medical Technology Services, INC. | $23.35 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.